SEC Comment Letter 0000000000-23-012336 to Inozyme Pharma, Inc. (CIK 0001693011)
Inozyme Pharma, Inc. (CIK 0001693011)
Date: Nov. 10, 2023 · CIK: 0001693011 · Accession: 0000000000-23-012336
AI Filing Summary & Sentiment
File numbers found in text: 333-275364
Letter
United States securities and exchange commission logo November 9, 2023 Douglas A. Treco Chief Executive Officer Inozyme Pharma, Inc. 321 Summer Street, Suite 400 Boston, MA 02210 Re:Inozyme Pharma, Inc. Registration Statement on Form S-3 Filed November 7, 2023 File No. 333-275364 Dear Douglas A. Treco: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Caroline Dotolo, Esq.
Show Raw Text
United States securities and exchange commission logo
November 9, 2023
Douglas A. Treco
Chief Executive Officer
Inozyme Pharma, Inc.
321 Summer Street, Suite 400
Boston, MA 02210
Re:Inozyme Pharma, Inc.
Registration Statement on Form S-3
Filed November 7, 2023
File No. 333-275364
Dear Douglas A. Treco:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Caroline Dotolo, Esq.